Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,044.66
-12.36 (-1.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
June 28, 2024
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell...
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
June 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading
March 22, 2024
Via
Investor Brand Network
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
June 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
May 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
May 19, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
May 17, 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
May 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Will the Biotech Sector Shift From Lagger to Leader?
May 10, 2024
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.
Via
MarketBeat
Topics
ETFs
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
May 08, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces Investor Conference Presentations
May 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Reports First Quarter 2024 Financial and Operating Results
May 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and...
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
April 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
April 24, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
April 22, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
April 18, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
April 17, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
April 11, 2024
From
Schall Law
Via
GlobeNewswire
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
April 07, 2024
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
April 01, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Provides Update on Biologics License Application for Odronextamab
March 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
March 12, 2024
$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.